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Metals such as platinum, gold, ruthenium, titanium and tin can be a source of biologically active
derivatives and, occasionally, become tools in the chemotherapy against different kinds of human
tumors. The preclinical evaluation includes not only antitumor activity tests but also the investi-
gation of the particular chemistry, the molecular targets within biological materials and the effect on
the survival of a cell within its particular environment.
These metals may form coordination compounds by binding ligands firmly or loosely, depending
on the chemical nature of both the metal ion and the ligands. A loosely coordinated chloride ion or
water molecule will exchange for a more nucleophilic biomolecule, commonly a nucleobase or a
sulfur-containing amino acid side chain, and thereby infer a biological lesion. A metal ion complex
may require an exchange of one or more ligands for water in order to become activated. All the
firmly bound, conserved, ligands influence both target selection and reactivity of the metal ion.
Following the important thesis of Collier and Krauss from the 30s ("The effect of a heavy metal on
experimental murine cancer is not only due to the metal alone, but also to the structure of the
compounds and the type of compound"), it should be emphasized that the efficacy of a metal
complex against cancer is primarily related to the kind of its set of ligands and to the resulting
substitution stability of the different bounded ligands.
Under this aspect, two new tumor-inhibiting metal complexes will be discussed in this article, the
ruthenium complex trans-lndazole-tetrachlorobis(indazole)ruthenate(lll) and the titanium complex
Budotitane (INN), cis-dlethoxybis(1-phenylbutane-1,3-dionato)titanium(IV) (Fig. 1).
Both compounds show the best activity in experimental tumor models among a huge amount of
corresponding derivatives that we have synthesized and tested before. Budotitane is now under
clinical studies in patients, and the ruthenium indazole complex is at an highly advanced preclinical
stage of development and will enter clinical studies soon. Another important ruthenium complex
Cl Cl
Fig. 1" The two complexes trans-lndazole-tetrachlorobis(indazole)ruthenate(lll), trans-Hlnd[RuCI4(ind)2],
and cis-dlethoxybis(1-phenylbutane-1,3-dionato)titanium(IV), Ti(bzac)2(OEt)2.
lW.A. Collier, F. Krauss, Zeitschrift fr Krebsforschung, 1931, 34, 527
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with two trans-standing imidazole ligands, trans-HIm[RuCi4(im)z], ICR, that shows nearly as
excellent results as the indazole compound, will be considered as well. For the selection of most
active complexes, a procedure has been developed in Heidelberg which is based on the combi-
nation of transplantable and autochthonous tumor models. After synthesis and chemical
characterisation, the compounds are compared on the basis of activity in various transplantable
tumor models. These models are chosen in such a way that most of the compounds from the new
types of substances to be examined show medium activity in each relevant model, with the result
that complexes with major or minor activity can clearly be distinguished. After optimising the
chemical structure, compounds with outstanding activity are further investigated in autochthonous
tumor models. We selected AMMN-induced colorectal tumors of the rat for our antitumor activity
tests. This autochthonous model has a high predictivity for the clinical situation (Fig. 2). Colorectal
tumors are responsible for the major share of total cancer mortality among humans today.
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Fig. 2: Test results of Budotitane and Hlnd[RuCI4(ind)2 against thls model are shown, compared to cisplatin
and 5-fluorouracil.
Cisplatin, cis-Diamminedichloroplatinum(ll), turned out to be totally ineffective, as is the case in
patients suffering from this kind of tumor. Budotitane and Hlnd[RuCI4(ind)2 show highly promising
effects against this important type of tumor, similar or even better than fluorouracil, which is the
only drug to exhibit activity against this tumor in human cancer patients.
in the case of cisplatin, which is clinically active mainly against testicular carcinomas and few other
types of tumors, the kinetical stability of the complex is an outstanding criterion for its use as a
therapeutical agent. A prevention of fast hydrolysis reactions leads our attention to other metals
that show hydrolysis stability similar to that of platinum(ll). Ruthenium(Ill) is well known for its
stability in aqueous solution; for the tumor-inhibiting complexes like Hlnd[RuCl4(ind)2 and Him
[RuCI4(im)2], a slow exchange of their ligands can be predicted (Fig. 3).
Fig. 3: Rate constants (s") for the water exchange of solvated transition metal ions, measured directly by
NMR or estimated from the rate constants for complex formation (--- NMR complex formation).
(Following Y. Ducommun and A.E. Merbach in Inorg. High Pressure Chem., Elsevier, 1986, B 17)
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HPLC investigations of Hlnd[RuCl4(ind)2 in H20 showed indeed a slow decomposition (in
physiological saline at 22C) with a rate of hardly 1% per hour. The initial formation of an aqua
complex could also be confirmed by the isolation of the complex aquatrichloro(1-methyl-
indazole)ruthenium(lll), [Ru(H20)Cla(1Melnd)2]-" The UV spectra of the aqua complex show a
characteristic absorption at 360 nm, which misses in the spectra of the initial complex 1Melnd
[RuCI4(1Melnd)2]. This absorption was the basis, of the assignment of the aqua complexes formed
during hydrolysis of Hlnd[RuCl,(ind)2]. The imidazole complex hydrolizes faster in physiological
saline (22C); after one hour nearly 3 % of the original complex has been substituted in solution.
Decrease in % (PEAK AREA) The respective imidazolium ion is the stronger base
and leads to a less acidic reaction milieu, the
concentration of nucleophiles (imidazole, chloride and
H20 is raised. The result is the observed loss of
stability of the imidazole complex in physiological
saline (Fig. 4). A general decrease in stability can be
observed when Hlnd[RuCI4(ind)2 is added to a
physiological buffer solution (0.1 M NaCI, 0.004 M
NaH2PO4, 0.025 M NaHCOa). A blue-green
precipitate is formed after 10 minutes (37C). These
investigations have been done in preparation of
experiments that showed us the interaction of Hind
[RuCl4(ind)2 and HIm[RuCi(im)2] in human serum.
The UV and HPLC studies of the reactions in phys.
Fig. 4: HPLC investigations into the hydrolytic buffer showed us that the imidazole complex is much
decomposition of HIm[RuCI4(im)2 (= 4) more stable than the corresponding indazole
and Hlnd[RuCI4(ind)2 (= *)in phys. compound. This is not surprising in view of the
saline at a temperature ot 22c. stronger basicity of the imidazole ligands. Assoziative
nucleophilic substitutions occur normally in the coordination sphere of ruthenium(Ill), a higher
electron density at the metal hinders a nucleophilic attack.
To obtain an insight into the molecular modes of intravenously administered antitumor metal
complexes, it is important to study the interactions of those with plasma proteins. For example, the
differences in efficacy, activity and toxicity between cisplatin and carboplatin are discussed in
relation to the measured differences in the reversibility of plasma binding of both compounds.
LPLC studies of Hlnd[RuCl(ind)2 showed that the major amount of the complex is bound to
albumin in serum (about 80 %). This is not surprising when we consider the amount present in
serum (approximately 42 weight per cent of the solutes) and the size of albumin. A small amount of
Hlnd[RuCl,(ind)2 is bound to transferrin, too. Ultrafiltration experiments have given evidence that
no binding to low molecular species (< M.W. 30.000) occurs. HPLC studies of the reaction rate
showed that binding to transferrin occurs within 5 minutes. After addition of citrate to the transferrin
adduct, free ruthenium complex could be observed in the HPLC that demonstrates the reversible
character of the binding. More details will be given in the abstract by F. Kratz in this book.
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Fig. 5: Pseudo first order decay of Ti(bzac)2(OEt)2
during hydrolysis of 20 mg of complex in
400 I1 of CD3OH + 20 !1 of D20 at 22C.
Budotitane, in contrast, belongs to the class of
rapidly hydrolysing metal complexes. If a 10.3 M
solution of Ti(bzac)2(OEt)2 is dissolved in
absolute acetonitrile, the addition of 20 vol.%
H20 leads to the decomposition of the complex
within a few minutes. A corresponding
experiment is shown in Fig. 5, it contains the
measurement of the decomposition of budo-
titane by the NMR signal of the Ti-O-CH2-CH3
protons. The primary product of the hydrolysis
of the two ethoxy groups of budotitane can be
obtained in a pure form by reaction of the
complex with water in the stoichiometric ratio of
1:2 in acetonitrile and subsequent evaporation
of the solvent and recrystallisation from
CCI4 / petroleum ether. Its composition is
[Ti(bzac)20],, which is probably produced
by oligomerisation of the intermediate
Ti(bzac)(OH)2 that is formed on the reaction of
budotitane with water. The molecular weight
(between n = 2 and n 3) could be confirmed
by vapour pressure osmometric measurements.
The much higher decomposition rate of budotitane has consequences for the galenic formulation of
the complex. A drug used in the clinic or in preclinical toxicological and pharmacological studies
must be relatively insensitive to hydrolysis; if it is not, a galenic formulation must guarantee these
properties. In the case of budotitane, the use of CremophorEL, a glycerinepolyethylene-
glycolericinoleate (BASF), is successful. Budotitane, CremophorEL and propylenglycole are
dissolved in water-free ethanol (weight ratio 1 9 1), the evaporated product is known as a
coprecipitate. In order to examine the decomposition of the complex in the watery micellar
emulsion, UV-spectra were taken and the levels of intact complex were calculated by component
analysis. Fig.6 shows that the major amount (80%) of the micellar emulsion, after a rapid
decomposition of 20% of the titanium complex, is stable over many hours in the region from 1 to 2
percent coprecipitate by weight in phys. saline. The initial rapid decomposition must probably be
attributed to the destruction of micelles that were defective from the start.
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Fig. 6: Time-dependent decomposition of budotitane in an aqueous micellar soludon of the coprecipitate.
a) 2% b) 1% coprecipitate by weight in isotonic solution.
Finally, the binding behaviour of the before discussed compounds towards DNA is presented in this
article. The kinetics of the metal complex-DNA binding have been measured with the help of an
ICP-AES (Induced Coupled Plasma-Atom Emission Spectrometer). The binding behaviour of Hind[
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RuCl,(ind)2 and HIm[RuCI4(im)2 (not shown) towards salmon testes DNA gives evidence that
similar amounts of metal bind to DNA with similar reaction rates. Interesting but not surprising is
the result of these measurements: the titanium complex shows the fastest reaction rate and the
best binding, due to its hardness (Fig. 7). It should be noted that both the new tumor-inhibiting
complexes budotitane and Hlnd[RuCI4(ind)2 show a high affinity to DNA; especially after one day
the measurements show a better binding to DNA than in the case of cisplatin. These results
correlate with the presented data of the activity in experimental tumor models and give us hope
that the compounds will show good results in the clinical studies.
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Fig. 7: Binding behaviour of Hlnd[RuCl(ind)2 and budotitane towards DNA, in comparison with cisplatin.
(10 mM NaCI, Salmon Testes DNA)
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